Hemophilia A (Haemophilia)

Subscribe to Selected New Research on Hemophilia A

4336 relevant articles (234 outcomes, 410 trials/studies) found for this Disease

Description: The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.

Also Known As:

Haemophilia; Hemophilia; Factor VIII Deficiency; Deficiency, Factor VIII; A, Hemophilia; As, Hemophilia; Deficiencies, Factor VIII; Factor VIII Deficiencies; Hemophilia As

Relationship Network

Disease Context: Research Results

Hemic and Lymphatic Diseases

Hematologic Diseases: 1420

Hemorrhagic Disorders: 447

Hemophilia A: 4336

Blood Coagulation Disorders: 86

Inherited Blood Coagulation Disorders: 30

Hemophilia A: 4336

Coagulation Protein Disorders

Hemophilia A: 4336

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 421

Inborn Genetic Diseases: 549

Inherited Blood Coagulation Disorders: 30

Hemophilia A: 4336

Related Diseases

1.	Hemorrhage
2.	von Willebrand Disease (von Willebrand's Disease)
3.	Hemophilia A (Haemophilia)
4.	Hemophilia B (Haemophilia B)
5.	Infection

Experts

1.	Yoshioka, A: 14 articles (08/2008 - 07/2000)
2.	Shima, M: 13 articles (08/2008 - 07/2000)
3.	Takamatsu, J: 9 articles (08/2006 - 01/2000)
4.	Lacroix-Desmazes, Sébastien: 8 articles (07/2008 - 02/2002)
5.	Bayry, Jagadeesh: 7 articles (07/2008 - 02/2002)
6.	Auerswald, G: 7 articles (01/2008 - 01/2001)
7.	Collins, P W: 7 articles (09/2007 - 10/2000)
8.	Tanaka, I: 7 articles (02/2006 - 02/2001)
9.	Yoshioka, Akira: 7 articles (01/2006 - 03/2002)
10.	Shima, Midori: 7 articles (05/2005 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hemophilia A:

1.	Factor VIII (Coagulation Factor VIII)IBA 05/15/1989 - "CONCLUSION: Factor VIII-CVP therapy is highly effective in the eradication of factor VIII inhibitor in nonhemophiliac patients but not in patients with hemophilia." 11/01/1999 - "These results suggest that PE is very effective in treating factor VIII inhibitor-positive acquired hemophilia." 08/01/2003 - "In conclusion, LD-PCR assay is a simple, rapid and accurate method for detection of factor VIII gene inversion, and this approach is helpful in screening, carrier testing, and prenatal diagnosis of severe hemophilia A." 03/01/2003 - "Blood loss was significantly greater in untreated hemophilia A mice compared to normal C57BL/6 mice, and in hemophilia A non-survivors that were treated with sub-therapeutic doses of factor VIII. The up-and-down method for small samples yielded an estimated dose of factor VIII producing survival in 50% of the mice (ED(50)) of 58 units/kg (95% confidence interval: 42.4-78.5 units/kg)" 09/01/1989 - "Three patients with low titer factor VIII inhibitors were treated successfully with constant infusion therapy, requiring a mean dose of factor VIII concentrate 2.3 fold (8.20 u/kg/h) higher than that of the patients without inhibitors (3.63 u/kg/h) to maintain a circulating plasma level of factor VIII of 1 u/ml. The use of constant infusion of clotting factor concentrates is safe, efficacious, and more convenient than bolus therapy of factor concentrates and should be considered for hospitalized hemophilia patients requiring replacement therapy." Order ALL the reference details at left...
2.	recombinant FVIIa (rFVIIa)IBA 03/01/2008 - "rFVIIa has been shown effective for prophylaxis during elective surgery and has therefore improved the feasibility of orthopedic surgery in hemophilia patients with high-titer inhibitors" 10/01/2003 - "In conclusion, should a TF-independent mechanism be involved in the efficacy of rFVIIa in patients with hemophilia, the superactive rFVIIa variants studied here might be clinically advantageous, as both procoagulant and antifibrinolytic potencies are significantly enhanced compared with those of wild-type rFVIIa" 09/01/2002 - "We have prospectively monitored treatment of haemophilia patients with inhibitors by recombinant factor VIIa (rFVIIa) administered by continuous infusion to obtain more insight in the underlying factors of the clinical efficacy of this administration method" 01/01/2007 - "In haemophilia patients with inhibitors, recombinant factor VIIa is clinically effective in controlling mild to moderate bleeds, and in maintaining haemostasis in patients undergoing orthopaedic surgery" 03/01/2008 - "The cumulative experience presented here suggests that rFVIIa is safe and effective for providing adequate haemostatic cover for haemophilia patients with inhibitors undergoing orthopaedic surgery" Order ALL the reference details at left...
3.	human F8 proteinIBA 03/01/2002 - "Advances in biotechnology allowed production of rFVIII at industrial scale, which significantly improved treatment of hemophilia A patients" 10/01/2000 - "The treatment of hemophilia A patients has improved in this decade by production of recombinant factor VIII (FVIII) in mammalian cells, which has significantly reduced contamination by infectious agents" 06/01/2002 - "Following demonstration of safety and efficacy with each rFVIII concentrate in previously treated patients with hemophilia A, studies in PUPs began" 03/01/2002 - "The study objectives were to assess the efficacy of KOGENATE Bayer (Kogenate FS) in achieving haemostasis during surgical procedures in patients with severe haemophilia A and to evaluate its safety when given in the doses needed for this purpose" 05/01/2005 - "The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update." Order ALL the reference details at left...
4.	Factor VIIa (Activated Factor VII)IBA 10/26/2001 - "Factor VIIa is also an important therapeutic agent for hemophilia where its function may include TF-independent as well as TF-dependent mechanisms" 08/01/1998 - "Recombinant activated factor VII: a new treatment for hemophilia]" 09/01/2008 - "Efficacy of different doses of recombinant activated factor VII in the treatment of haemophilia children with inhibitor." 11/15/2003 - "Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A." 02/01/2002 - "The efficacy of factor VIIa (10-50 nM) in hemophilia blood is dependent on TF." Order ALL the reference details at left...
5.	AntibodiesIBA 07/01/2008 - "Currently, the main problem in patients with haemophilia is the onset of antibodies inactivating the infused clotting factor (inhibitors), even though immune tolerance regimens that are able to eradicate inhibitors and the availability of products that bypass the intrinsic coagulation defects have dramatically improved the management of these patients" 06/01/2007 - "The CANAL Study (Concerted Action on Neutralizing Antibodies in severe hemophilia A) was designed to describe the relationship between treatment characteristics and inhibitor development in previously untreated patients with severe hemophilia A" 04/15/2006 - "The aim of the Malmö International Brother Study (MIBS) is to evaluate host genetic factors associated with the development of inhibitory antibodies in patients with hemophilia" 12/01/2003 - "The results of the present study are in contrast to and fail to confirm previously published reports showing a higher incidence of non-inhibitory antibodies in hemophilia A." 06/01/1997 - "The aim of our study was to investigate whether haemophilia A patients with inversion of intron 22 are at high risk for non-inhibitory anti-FVIII antibodies development detected by ELISA" Order ALL the reference details at left...
6.	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 05/01/2002 - "CONCLUSION: We conclude that administration of 150 microg of high concentration intranasal desmopressin is safe and effective in patients weighing < or = 50 kg with mild hemophilia A or mild type 1 VWD." 09/01/2002 - "Desmopressin is not always effective in mild haemophilia A patients undergoing urological surgery: the need of standardized protocols." 10/28/1987 - "Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies." 03/01/2001 - "The PFA-100 was also evaluated as a part of the laboratory monitoring procedure in patients with either vWD or haemophilia undergoing a DDAVP trial as a therapeutic management process" 05/01/1991 - "Four German Shepherd dogs with mild hemophilia A were given Desmopressin (Minirin intranasal solution, Ferring, Malmo, Sweden) subcutaneously at a range of doses in a controlled blind study" Order ALL the reference details at left...
7.	Factor IX (PTC)FDA LinkGeneric 07/01/1999 - "Since in most countries carrier detection is based on factor IX coagulant activity (FIX:C) assay, this study was designed to determine whether carriers' FIX:C values are dependent on the severity of haemophilia (mild, moderate or severe) or on the genetic anomaly in the family" 08/10/1997 - "In the case of factor IX, we have produced a high-titer adenovirus vector capable of transducing gut epithelial cells resulting in synthesis of factor IX. The results of our in vitro studies indicate that gene transfer targeting gut epithelium as a new approach to hemophilia gene therapy is rational and merits in vivo studies in hemophilia animal models." 07/01/1995 - "Gene therapy is a potential treatment for hemophilia, wherein cells transduced with a normal factor IX gene could provide a continuous in vivo source of circulating factor IX. In this study, we examined the potential use of hematopoietic cells as a target for factor IX gene therapy" 05/01/1953 - "Studies on a new hemorrhagic diseases similar to hemophilia; plasma thromboplastin component deficiency.]" 01/01/2008 - "Factor IX gene therapy for hemophilia." Order ALL the reference details at left...
8.	Blood Coagulation Factors (Coagulation Factor)IBA 01/01/2006 - "Plasma-derived concentrates of coagulation factors VIII and IX allow for effective treatment of haemophilia A and B" 12/28/2002 - "It has been shown that this treatment is effective in patients with haemophilia and an inhibiting antibody against a coagulation factor" 06/01/2000 - "The availability of new safe coagulation factors has improved the prognosis of haemophilia." 04/01/2004 - "Coagulation factors with improved properties for hemophilia gene therapy." 01/01/1982 - "Therapy with concentrated coagulation factors has greatly improved the management of hemophilia, but the consequence of repeated infusion of these blood products are unknown" Order ALL the reference details at left...
9.	rituximab (Mabthera)FDA Link 05/01/2006 - "Rituximab may be beneficial for patients with severe haemophilia and inhibitors in whom standard therapies have failed, but larger prospective studies are required to determine safety, efficacy and predictors of success." 06/01/2006 - "CONCLUSIONS: Although data are limited, administration of rituximab appears to be an effective option for treatment of patients with acquired hemophilia after established therapies have failed" 04/01/2006 - "The hemophilia followed a relapsing course under oral corticosteroid therapy, but B-cell depletion with anti-CD20 monoclonal antibody (rituximab) was effective in inducing a prolonged remission." 06/15/2004 - "In conclusion, rituximab appears an effective and well-tolerated treatment for patients with acquired hemophilia and low inhibitor titers" 01/01/2008 - "Efficacy of rituximab treatment in postpartum acquired haemophilia A." Order ALL the reference details at left...
10.	prothrombin complex concentrates (PPSB)IBA 03/01/1999 - "Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery." 09/01/1983 - "Studies of factor IX concentrate therapy in hemophilia." 01/01/2002 - "Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors." 09/01/2000 - "A retrospective case analysis of the use of Autoplex T (anti-inhibitor coagulant complex [heat treated]) at a major haemophilia treatment centre is described" 09/01/1999 - "Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors." Order ALL the reference details at left...

Therapies and Procedures

1.	Liver Transplantation 07/01/2008 - "Liver transplantation is the only potentially curative treatment available for these patients, providing a long-term phenotypic cure for hemophilia" 10/01/2005 - "An ideal setting to study this problem is in individuals with hemophilia A following liver transplantation, as their FVIII is synthesized primarily in hepatic, but not extrahepatic endothelial cells, while VWF is synthesized primarily in extrahepatic vascular endothelium" 05/01/2005 - "Preclinical experiment of auxiliary partial orthotopic liver transplantation as a curative treatment for hemophilia." 04/01/2005 - "It is well recognized that liver transplantation can cure haemophilia" 05/01/2003 - "Acquired hemophilia A after liver transplantation: a case report." Order ALL the reference details at left...
2.	Transplants (Transplant) 05/01/2005 - "However, it is not known whether the graft of APOLT would be enough to cure hemophilia" 06/27/2002 - "Furthermore, a graft from a living-related donor with hemophilia A carrier seems to be suitable provided such individuals receive adequate support for coagulopathies." 07/02/1970 - "Splenic transplant for hemophilia." 05/24/1969 - "Organ transplant for haemophilia." 01/01/1969 - "Attempted spleen transplant in classical hemophilia." Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 10/01/2008 - "Our further studies showed that transplantation with 1% to 5% 2bF8(tg+/-) BM cells still improved hemostasis in hemophilia A mice with inhibitors" 02/01/2007 - "OBJECTIVE: In this study, we assessed the efficacy of using a genetic therapy approach to correct haemophilia A in FVIII-deficient (FVIII(null)) mice by transplantation of bone marrow (BM) transduced with a lentivirus (LV)-based gene transfer cassette encoding 2bF8" 05/15/2006 - "In this study, we evaluated ex vivo retroviral gene transfer of a high-expression porcine fVIII transgene into bone marrow-derived stromal and hematopoietic stem/progenitor cells (MSCs and HSCs, respectively) and transplantation into genetically immunocompetent hemophilia A mice" 06/01/2007 - "Recently, we demonstrated that transplantation of genetically modified hematopoietic stem cells containing a high-expression porcine fVIII transgene promoted sustained high-level fVIII expression in naïve hemophilia A mice" 02/01/2007 - "CONCLUSIONS: These results demonstrate that ectopic expression of FVIII in platelets by lentivirus-mediated bone marrow transduction/transplantation may be a promising strategy for gene therapy of haemophilia A in humans." Order ALL the reference details at left...
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 07/01/1991 - "The success of gene transfer by liver and bone marrow transplantation in porcine vWD and canine hemophilia A, with a change in phenotype that establishes improved hemostasis, portends imminent testing of gene therapy in these models" 07/01/2001 - "Over the past decade, bone marrow transplantation has come to be considered an ideal therapeutic strategy for the treatment of certain diseases affecting the hematopoietic system such as hemophilia, and several clinical trials have been performed" 03/01/2006 - "Allogeneic bone marrow transplantation in a child with severe aplastic anemia and hemophilia A." 11/01/2004 - "STUDY DESIGN AND SETTING: We enrolled families of children admitted for cancer chemotherapy and those attending outpatient rheumatology, hemophilia and bone marrow transplantation clinics" 10/01/2004 - "To explore the possibility of utilizing autologous bone marrow transplantation of genetically modified hematopoietic stem cells for hemophilia gene therapy, we investigated the efficacy of genetically engineered CD34+ cell transplantation to NOD/SCID mice for expression of human factor VIII (hFVIII)" Order ALL the reference details at left...
5.	Arthroplasty 09/01/2000 - "A search of the literature showed that a number of studies describing the use of total knee arthroplasty (TKA) and total hip arthroplasty (THA) in haemophilia have been published, whereas shoulder, elbow and ankle arthroplasties are confined to case reports" 03/01/1999 - "There are few published studies of the long term results of total knee arthroplasties in patients with hemophilia" 09/01/2008 - "With the availability of clotting factor concentrates, advances in surgical techniques, better implant design, and improvements in postoperative management, total knee arthroplasty has become the treatment of choice for haemophilia patients suffering from end-stage haemophilic knee arthropathy" 09/01/2008 - "The role of physiotherapy after total knee arthroplasty in patients with haemophilia." 01/01/2008 - "The impact of haemophilia on the success of total hip arthroplasty." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Hemophilia A

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 234 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>